TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26514619
Drug: 5-aminolevulinic acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid (ALA) with sodium ferrous citrate (SFC) (100 and 115 mg/day)
Study: 22160495
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (2 g/day for 8 weeks)
Study: 21056806
Drug: Preemptive lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preemptive lidocaine 4 mL mixed with propofol 20 mL
Study: 21056806
Drug: Preemptive lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preemptive lidocaine 4 mL mixed with etomidate 20 mL
Study: 21056806
Drug: Simultaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous treatment with lidocaine 4 mL mixed with propofol 20 mL
Study: 21056806
Drug: Simultaneous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous treatment with lidocaine 4 mL mixed with etomidate 20 mL
Study: 16297689
Drug: 0.75 mg/mL
Normalized name: digoxin 0.75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/mL rhBMP-2/ACS
Study: 16297689
Drug: 1.50 mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.50 mg/mL rhBMP-2/ACS
Study: 7594348
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg q.d. plus ampicillin 500 mg b.i.d.
Study: 7594348
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg b.i.d. plus ampicillin 500 mg b.i.d.
Study: 471256
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (31 patients, uniform intervention on primary risk factors and medical therapy)
Study: 22522672
Drug: Vardenafil 10
Normalized name: vardenafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 10 mg single dose (group B)
Study: 22522672
Drug: Vardenafil 10
Normalized name: vardenafil 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil 10 mg every other day for 15 days (group C)
Study: 19221595
Drug: Topical paromomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical paromomycin (PR) with methylbenzethonium chloride (MBCL)
Study: 19221595
Drug: Topical paromomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical paromomycin (PR)
Study: 19221595
Drug: Parenteral paromomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral paromomycin (PR)
Study: 19221595
Drug: Topical or
Normalized name: aloe vera topical oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical or parenteral paromomycin (PR)
Study: 9823137
Drug: Corticosteroid-antibiotic solution
Normalized name: antibiotics in combination with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid-antibiotic solution
Study: 7704924
Drug: Trivalent oral
Normalized name: poliovirus vaccine, live, trivalent oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent oral poliovirus vaccine (TOPV) given at birth, 6 weeks, 10 weeks, and 14 weeks after birth
Study: 7704924
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group omitted the dose at birth
Study: 2653972
Drug: Loperamide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (2 mg capsules, two on entry and one after each unformed stool up to a maximum of eight per day)
Study: 373661
Drug: Terbutaline sulfate,
Normalized name: Terbutaline Sulfate, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline sulfate, 5 mg
Study: 373661
Drug: Ephedrine sulfate,
Normalized name: EPHEDrine Sulfate, 25 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine sulfate, 25 mg
Study: 373661
Drug: Aminophylline, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline, 400 mg
Study: 31875646
Drug: GFRAL-antagonist antibody
Normalized name: digoxin antibodies Fab fragments
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFRAL-antagonist antibody
Study: 26466219
Drug: Morphine (0.1mg/kg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.1mg/kg, max 5mg) associated with midazolam (0.2mg/kg, max 10mg)
Study: 24416905
Drug: Manipulation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulation of Traditional Chinese Medicine (TCM)
Study: 15240190
Drug: IFN beta-1b
Normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN beta-1b standard dose (250 microg every other day)
Study: 8772552
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (100-400 ng/kg-day ethinyl estradiol)
Study: 25573347
Drug: Garlic powder
Normalized name: Garlic Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic powder tablet (1200 µg allicin/tab) twice daily for 3 months
Study: 19274696
Drug: Benzyl benzoate
Normalized name: Benzyl Benzoate
DrugBank: Benzyl benzoate (DB00676)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzyl benzoate lotion
Study: 11028944
Drug: Scopolamine hydrobromide
Normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine hydrobromide 0.2 mg at pH 4.0
Study: 11028944
Drug: Scopolamine hydrobromide
Normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine hydrobromide 0.2 mg at pH 7.0
Study: 11028944
Drug: Scopolamine hydrobromide
Normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine hydrobromide 0.2 mg at pH 9.0
Study: 11028944
Drug: Scopolamine hydrobromide
Normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine hydrobromide 0.4 mg at pH 4.0
Study: 11028944
Drug: Scopolamine hydrobromide
Normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine hydrobromide 0.4 mg at pH 7.0
Study: 11028944
Drug: Scopolamine hydrobromide
Normalized name: Scopolamine Hydrobromide
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine hydrobromide 0.4 mg at pH 9.0
Study: 9200654
Drug: Lisinopril 10-20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10-20 mg/day
Study: 9200654
Drug: Atenolol 50-100
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50-100 mg/day
Study: 8256699
Drug: Extended-release isosorbide
Normalized name: isosorbide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release isosorbide mononitrate 30, 60, 120 or 240 mg once daily
Study: 8256699
Drug: Extended-release isosorbide
Normalized name: isosorbide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release isosorbide mononitrate 120 or 240 mg once daily
Study: 2863998
Drug: Atracurium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.6 mg/kg (group A; n = 11)
Study: 2863998
Drug: Fazadinium 1
Normalized name: fazadinium bromide
DrugBank: Fazadinium bromide (DB13745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fazadinium 1 mg/kg (group F; n = 11)
Study: 25040799
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 3 g a day
Study: 16100174
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (intermittent nCPAP 10 cm H2O for 10 min every 4 h)
Study: 1755531
Drug: NLA in
Normalized name: Ngenla Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLA in combination with epidural opiate analgesia (group 2)
Study: 1755531
Drug: NLA in
Normalized name: Ngenla Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLA in combination with local anesthesia (group 3)
Study: 1755531
Drug: Epidurally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidurally administered morphine (group 2)
Study: 6804222
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg DPM (dipropylacetamide) taken after a standard meal
Study: 6804222
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg DPM (dipropylacetamide) taken in a fasting state
Study: 24349052
Drug: Ataluren 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ataluren 10, 10, 20 mg/kg
Study: 22550833
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose pantoprazole bolus injections (40 mg twice daily for 7 days)
Study: 22550833
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of pantoprazole (8 mg per hour for first 3 days, then 40 mg bolus twice daily for 4-7 days)
Study: 22550833
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose pantoprazole bolus injections
Study: 22550833
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of pantoprazole
Study: 17086540
Drug: Dysfunctional Attitude
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dysfunctional Attitude Scale (DAS) scores at the beginning of continuation treatment
Study: 15022126
Drug: Once-daily 2.5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily 2.5-mg rhDNase
Study: 15022126
Drug: Alternate-day 2.5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day 2.5-mg rhDNase
Study: 15022126
Drug: Twice-daily 5
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily 5 ml of 7% hypertonic saline (HS)
Study: 9772930
Drug: Benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 10 mg once daily for 8 weeks
Study: 9772930
Drug: Benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril 10 mg once daily for 4 weeks, then Hydrochlorothiazide 12.5 mg once daily for the last 4 weeks if DBP > 90 mmHg
Study: 8170729
Drug: PRP-T with
Normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-T with diphtheria toxoid vaccine
Study: 8170729
Drug: PRP-OMP with
Normalized name: Hib (PRP-OMP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRP-OMP with diphtheria-tetanus toxoid vaccine
Study: 8170729
Drug: Diphtheria-tetanus toxoid
Normalized name: diphtheria-tetanus toxoids (DT) ped
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria-tetanus toxoid vaccine
Study: 12787692
Drug: 100% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% oxygen (treatment group)
Study: 12579906
Drug: Single plate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single plate Molteno implant
Study: 6387183
Drug: 1-day treatment
Normalized name: 30 day Acne Treatment Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-day treatment regimen
Study: 6387183
Drug: 10-day treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day treatment regimen
Study: 24680372
Drug: Suvorexant (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant (40 mg for patients younger than 65 years, 30 mg for patients aged 65 years or older)
Study: 22508924
Drug: 5 S's
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 S's with sucrose (24% oral sucrose)
Study: 22508924
Drug: Sucrose alone
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose alone (2 mL of 24% oral sucrose)
Study: 22508924
Drug: Control (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2 mL of water with standard-of-care comfort measures)
Study: 20820114
Drug: Special mouth
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special mouth care with essential oil (geranium, lavender, tea tree, and peppermint) applied twice daily for one week
Study: 20820114
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline mouth care applied twice daily for one week
Study: 18210330
Drug: tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tibolone 2.5 mg daily for 16 weeks
Study: 18210330
Drug: 17beta-estradiol 2
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17beta-estradiol 2 mg daily for 16 weeks
Study: 22277987
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no hormone therapy)
Study: 1667334
Drug: Baclofen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (10 mg PO at 0830h)
Study: 6406531
Drug: Phosphate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate therapy (8.5 mmol/h or approximately 6 g phosphate/24 h)
Study: 6406531
Drug: No phosphate
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No phosphate therapy (control group)
Study: 24708645
Drug: First-line antiretroviral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line antiretroviral therapy (ART)
Study: 24708645
Drug: Baseline genotyping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline genotyping for HIV drug resistance (HIVDR)
Study: 23067427
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy component of CPT (n = 39)
Study: 11454122
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen (0.625 mg) combined with progesterone (2.5 mg)
Study: 9548613
Drug: Lansoprazole, amoxicillin,
Normalized name: Lansoprazole, Amoxicillin, Clarithromycin KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, amoxicillin, and clarithromycin triple therapy
Study: 8047821
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amoxycillin (3 g daily), metronidazole (1 g daily), and omeprazole (20 mg daily)
Study: 19846027
Drug: Febuxostat (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (80 mg or 120 mg daily)
Study: 19846027
Drug: Allopurinol (300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300/100 mg/day)
Study: 17464087
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow cell (BMC) transplantation and GM-CSF administration (n = 17, 14 days post-injury)
Study: 17464087
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow cell (BMC) transplantation and GM-CSF administration (n = 6, between 14 days and 8 weeks post-injury)
Study: 17464087
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow cell (BMC) transplantation and GM-CSF administration (n = 12, more than 8 weeks post-injury)
Study: 15044639
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy plus autologous stem-cell transplantation
Study: 15044639
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy plus autologous stem-cell transplantation (for high intermediate risk patients)
Study: 8519044
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg or 20 mg
Study: 8519044
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg plus hydrochlorothiazide 25 mg
Study: 19000191
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (ER:YAG laser ablation + 5FU application + NB-UVB therapy)
Study: 19000191
Drug: Mono-therapy (NB-UVB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mono-therapy (NB-UVB therapy only)
Study: 16640106
Drug: 3TC (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3TC (4 mg/kg/day, max 100 mg) started simultaneously with IFN‐alpha2a for 6 months (group I)
Study: 3440643
Drug: Microporous colestyramine
Normalized name: colestyramine
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microporous colestyramine (MPC) 9 g/day
Study: 3440643
Drug: Microporous colestyramine
Normalized name: colestyramine
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microporous colestyramine (MPC) 12 g
Study: 3440643
Drug: Microporous colestyramine
Normalized name: colestyramine
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microporous colestyramine (MPC) 18 g
Study: 26382589
Drug: Anti-TNF agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF agents
Study: 26324284
Drug: Preemptive multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive multimodal analgesic regimen (celecoxib, pregabalin, extended‐release oxycodone, and acetaminophen)
Study: 15645698
Drug: Insulin dosage
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin dosage calculation device (IDC)
Study: 12503831
Drug: Dothiepin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin (75 mg/day for 1 week followed by 150 mg/day for 4 weeks)
Study: 9692699
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg o.m.
Study: 29535280
Drug: Aromatherapy (inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy (inhalation of aroma oil blended with lavender, ylang-ylang, and neroli at a ratio of 4:2:1, twice before and after CAG)
Study: 23725162
Drug: Transcatheter arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter arterial infusion (TAI)
Study: 20605308
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with platform switching (test)
Study: 20605308
Drug: Control implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control implants with horizontally matching implant-abutment connection (control)
Study: 20605308
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between test and control implants
Study: 18206919
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bremelanotide as an intranasal spray
Study: 8625682
Drug: Milrinone loading
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone loading dose of 25 micrograms/kg (LOW) followed by infusion of 0.5 microgram/kg/min
Study: 8625682
Drug: Milrinone loading
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone loading dose of 50 micrograms/kg (MED) followed by infusion of 0.5 microgram/kg/min
Study: 8625682
Drug: Milrinone loading
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone loading dose of 75 micrograms/kg (HIGH) followed by infusion of 0.5 microgram/kg/min
Study: 8625682
Drug: Milrinone administration
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone administration (all doses)
Study: 6489414
Drug: Cisapride (novel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (novel enterokinetic agent)
Study: 30708075
Drug: Intravenous adrenaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous adrenaline
Study: 25045257
Drug: Bisphosphonates (risedronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonates (risedronate 35 mg weekly) for 12 months
Study: 25045257
Drug: Bisphosphonates along
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonates along with nutritional supplementation (40 g protein, 600 kcal daily) for the first 6 months
Study: 22278377
Drug: Sequential intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential intravenous 5‐FU at 800 mg/m2 for 5 days every 4 weeks followed by weekly PTX at 80 mg/m2
Study: 22278377
Drug: Sequential S‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential S‐1 at 80 mg/m2 for 4 weeks and 2-week rest followed by PTX
Study: 22278377
Drug: Concurrent intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent intravenous 5‐FU at 600 mg/m2 for 5 days and weekly PTX at 80 mg/m2 every 4 weeks
Study: 22278377
Drug: Concurrent S‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent S‐1 for 14 days and PTX at 50 mg/m2 on days 1 and 8 every 3 weeks
Study: 16275232
Drug: Ethinyl E2
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ethinyl E2 plus cyproterone acetate (0.01 mg + 3 mg/day)
Study: 16275232
Drug: Norethindrone acetate
Normalized name: Norethindrone Acetate
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norethindrone acetate (2.5 mg/day)
Study: 7755224
Drug: 300 mg/d
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/d of ursodeoxycholic acid
Study: 7755224
Drug: 600 mg/d
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/d of ursodeoxycholic acid
Study: 7755224
Drug: 1200 mg/d
Normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg/d of ursodeoxycholic acid
Study: 7840022
Drug: Biologically standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologically standardized extract of mites (active therapy)
Study: 7840022
Drug: Saline buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline buffered solution (placebo)